Establishment Labs posts 45% revenue growth on U.S. launch, refinances $300M debt facility

Filed May 8, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 9, 2025 · ~1 min read

Key Changes

• high

  Revenue surged 45% to $59.9M in Q1 2026 vs $41.4M prior year, driven by $13.5M increase in U.S. sales following September 2024 FDA approval. Net loss improved 35% to $13.4M from $20.7M.

  MD&A: Revenue and Net Loss verify on EDGAR →
• high

  Company refinanced debt in April 2026, increasing facility from $225M to $300M and drawing $265M to repay prior obligations. Interest expense rose 21% to $7.1M quarterly.

  MD&A: Debt Refinancing verify on EDGAR →
• high

  Gross margin expanded 350 basis points to 70.7% from 67.2%, driven by higher U.S. pricing, while SG&A growth decelerated to 10% vs 37% prior year, demonstrating operating leverage.

  MD&A: Margins and Operating Expenses verify on EDGAR →